Broad-Spectrum Antiviral Strategies and Nucleoside Analogues
The emergence or re-emergence of viruses with epidemic and/or pandemic potential, such as Ebola, Zika, Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus 1 and 2 (SARS and SARS-CoV-2) viruses, or new strains of influenza represents significant human health thr...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/4/667 |
| _version_ | 1797537908891058176 |
|---|---|
| author | Robert J. Geraghty Matthew T. Aliota Laurent F. Bonnac |
| author_facet | Robert J. Geraghty Matthew T. Aliota Laurent F. Bonnac |
| author_sort | Robert J. Geraghty |
| collection | DOAJ |
| description | The emergence or re-emergence of viruses with epidemic and/or pandemic potential, such as Ebola, Zika, Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus 1 and 2 (SARS and SARS-CoV-2) viruses, or new strains of influenza represents significant human health threats due to the absence of available treatments. Vaccines represent a key answer to control these viruses. However, in the case of a public health emergency, vaccine development, safety, and partial efficacy concerns may hinder their prompt deployment. Thus, developing broad-spectrum antiviral molecules for a fast response is essential to face an outbreak crisis as well as for bioweapon countermeasures. So far, broad-spectrum antivirals include two main categories: the family of drugs targeting the host-cell machinery essential for virus infection and replication, and the family of drugs directly targeting viruses. Among the molecules directly targeting viruses, nucleoside analogues form an essential class of broad-spectrum antiviral drugs. In this review, we will discuss the interest for broad-spectrum antiviral strategies and their limitations, with an emphasis on virus-targeted, broad-spectrum, antiviral nucleoside analogues and their mechanisms of action. |
| first_indexed | 2024-03-10T12:22:56Z |
| format | Article |
| id | doaj.art-2aad3b9579a3437f862d8ed9e6628b9c |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T12:22:56Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-2aad3b9579a3437f862d8ed9e6628b9c2023-11-21T15:17:11ZengMDPI AGViruses1999-49152021-04-0113466710.3390/v13040667Broad-Spectrum Antiviral Strategies and Nucleoside AnaloguesRobert J. Geraghty0Matthew T. Aliota1Laurent F. Bonnac2Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USADepartment of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN 55108, USACenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USAThe emergence or re-emergence of viruses with epidemic and/or pandemic potential, such as Ebola, Zika, Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus 1 and 2 (SARS and SARS-CoV-2) viruses, or new strains of influenza represents significant human health threats due to the absence of available treatments. Vaccines represent a key answer to control these viruses. However, in the case of a public health emergency, vaccine development, safety, and partial efficacy concerns may hinder their prompt deployment. Thus, developing broad-spectrum antiviral molecules for a fast response is essential to face an outbreak crisis as well as for bioweapon countermeasures. So far, broad-spectrum antivirals include two main categories: the family of drugs targeting the host-cell machinery essential for virus infection and replication, and the family of drugs directly targeting viruses. Among the molecules directly targeting viruses, nucleoside analogues form an essential class of broad-spectrum antiviral drugs. In this review, we will discuss the interest for broad-spectrum antiviral strategies and their limitations, with an emphasis on virus-targeted, broad-spectrum, antiviral nucleoside analogues and their mechanisms of action.https://www.mdpi.com/1999-4915/13/4/667broad-spectrum antiviralslethal mutagenesischain terminatornucleoside analogues |
| spellingShingle | Robert J. Geraghty Matthew T. Aliota Laurent F. Bonnac Broad-Spectrum Antiviral Strategies and Nucleoside Analogues Viruses broad-spectrum antivirals lethal mutagenesis chain terminator nucleoside analogues |
| title | Broad-Spectrum Antiviral Strategies and Nucleoside Analogues |
| title_full | Broad-Spectrum Antiviral Strategies and Nucleoside Analogues |
| title_fullStr | Broad-Spectrum Antiviral Strategies and Nucleoside Analogues |
| title_full_unstemmed | Broad-Spectrum Antiviral Strategies and Nucleoside Analogues |
| title_short | Broad-Spectrum Antiviral Strategies and Nucleoside Analogues |
| title_sort | broad spectrum antiviral strategies and nucleoside analogues |
| topic | broad-spectrum antivirals lethal mutagenesis chain terminator nucleoside analogues |
| url | https://www.mdpi.com/1999-4915/13/4/667 |
| work_keys_str_mv | AT robertjgeraghty broadspectrumantiviralstrategiesandnucleosideanalogues AT matthewtaliota broadspectrumantiviralstrategiesandnucleosideanalogues AT laurentfbonnac broadspectrumantiviralstrategiesandnucleosideanalogues |